Skip to main content
. 2021 Nov 1;186(1):40–49. doi: 10.1111/bjd.20655

Table 1.

Demographic and baseline clinical characteristics

Vehicle (n = 83) Difamilast 0·3% (n = 83) Difamilast 1% (n = 85)
Mean (SD) age (years) 7·1 (2·8) 7·1 (3·3) 7·2 (3·2)
Male 49 (59) 38 (46) 48 (56)
Mean (SD) weight (kg) 24·6 (9·7) 25·7 (11·8) 25·7 (12·5)
Mean (SD) height (cm) 120·3 (17·4) 120·8 (21·2) 121·2 (20·7)
Mean (SD) BMI (kg m–2) 16·3 (2·0) 16·6 (2·5) 16·5 (2·6)
Mean (SD) duration of AD (years) 5·5 (2·8) 5·0 (3·2) 5·1 (3·0)
IGA score
Mild disease (2) 12 (15) 13 (16) 14 (16)
Moderate disease (3) 71 (86) 70 (84) 71 (84)
Severity of ADa
Mild 8 (10) 8 (10) 9 (11)
Moderate 55 (66) 58 (70) 57 (67)
Severe 20 (24) 17 (20) 19 (22)
Mean (SD) EASI score 11·3 (5·9) 10·8 (5·5) 11·6 (5·5)
Mean (SD) POEM score 9·7 (4,7) 11·2 (5·3) 10·1 (5·4)
Mean (SD) VRS pruritus score (for patients aged 7–14 years) 1·9 (0·6) 1·9 (0·5) 1·9 (0·6)
Affected BSA (%)
≥ 5 to < 10 13 (16) 12 (14) 11 (13)
≥ 10 to < 30 46 (55) 53 (64) 54 (64)
≥ 30 24 (29) 18 (22) 20 (24)

Data are n (%) unless otherwise indicated. AD, atopic dermatitis; BMI, body mass index; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; POEM, Patient‐Oriented Eczema Measure; VRS, Verbal Rating Scale. aJapanese severity index of AD was based on the ‘Guidelines for the Treatment of Atopic Dermatitis 2008’ of Health and Labour Sciences Research.